1. Home
  2. ADAP vs HUIZ Comparison

ADAP vs HUIZ Comparison

Compare ADAP & HUIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • HUIZ
  • Stock Information
  • Founded
  • ADAP 2008
  • HUIZ 2006
  • Country
  • ADAP United Kingdom
  • HUIZ China
  • Employees
  • ADAP N/A
  • HUIZ N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • HUIZ Specialty Insurers
  • Sector
  • ADAP Health Care
  • HUIZ Finance
  • Exchange
  • ADAP Nasdaq
  • HUIZ Nasdaq
  • Market Cap
  • ADAP 21.3M
  • HUIZ 25.3M
  • IPO Year
  • ADAP 2015
  • HUIZ 2020
  • Fundamental
  • Price
  • ADAP $0.06
  • HUIZ $4.21
  • Analyst Decision
  • ADAP Hold
  • HUIZ Hold
  • Analyst Count
  • ADAP 6
  • HUIZ 1
  • Target Price
  • ADAP $1.02
  • HUIZ $2.30
  • AVG Volume (30 Days)
  • ADAP 62.3M
  • HUIZ 664.3K
  • Earning Date
  • ADAP 11-12-2025
  • HUIZ 09-12-2025
  • Dividend Yield
  • ADAP N/A
  • HUIZ N/A
  • EPS Growth
  • ADAP N/A
  • HUIZ N/A
  • EPS
  • ADAP N/A
  • HUIZ 0.25
  • Revenue
  • ADAP $65,084,999.00
  • HUIZ $186,519,166.00
  • Revenue This Year
  • ADAP N/A
  • HUIZ $11.94
  • Revenue Next Year
  • ADAP $52.35
  • HUIZ $8.15
  • P/E Ratio
  • ADAP N/A
  • HUIZ $16.77
  • Revenue Growth
  • ADAP N/A
  • HUIZ 19.12
  • 52 Week Low
  • ADAP $0.04
  • HUIZ $1.50
  • 52 Week High
  • ADAP $1.17
  • HUIZ $10.58
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 38.42
  • HUIZ 85.07
  • Support Level
  • ADAP $0.06
  • HUIZ $2.70
  • Resistance Level
  • ADAP $0.07
  • HUIZ $2.63
  • Average True Range (ATR)
  • ADAP 0.01
  • HUIZ 0.18
  • MACD
  • ADAP 0.01
  • HUIZ 0.12
  • Stochastic Oscillator
  • ADAP 53.33
  • HUIZ 85.29

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

About HUIZ Huize Holding Limited

Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.

Share on Social Networks: